<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

INS 2019 Preview: An Interview with INS President Robert Levy, MD

Posted by Anne Staylor on 5/20/19 12:59 PM

In an interview with SmartTRAK, Robert Levy, MD, president of the International Neuromodulation Society (INS), provides a preview of the research, emerging technologies, and trends in neuromodulation that will be at the INS 2019 14th World Congress to be held May 23-30, 2019 in Sydney, Australia. 

The meeting will highlight several important topics, including the use of neurostimulation to reduce opioid use, closed-loop neurostimulation, and advances in non-invasive brain stimulation, including for the treatment of post-traumatic stress disorder, depression, and for enhancing memory and learning.

In terms of research, Dr. Levy said Sam Eldabe, MD of the United Kingdom will provide a critical evaluation of clinical trials in neuromodulation. Researchers will also present the latest insight into mechanism of action, new data on neurostimulation for cardiac ischemia, as well as research on use of deep brain stimulation (DBS) for obesity, eating disorders and addiction. Researchers will also present important pivotal trial results, including: the Evoke Study (Saluda Medical), evaluating closed-loop spinal cord stimulation (SCS); the SURF study (Stimwave Technologies), comparing different wireless SCS frequencies and waveforms; and the ReActiv8 trial (Mainstay Medical), evaluating the use of a restorative neurostimulation system for nocioceptive chronic low back pain. 

On the technology front, the INS’s Innovation Day will highlight disruptive innovations in neuromodulation, and will feature panel discussions and presentations by researchers and major shareholders from early stage start-ups, middle-stage start-ups and well-established companies.

To find out more about the INS World Congress, click on the following video to listen to SmartTRAK’s interview with Dr. Levy recorded via phone from his office in Florida. A transcript of the interview is also provided below.

Read More

Topics: Neuromodulation, SmartTRAK Interviews

NANS 2019 Preview: SmartTRAK Interviews Todd Sitzman, MD

Posted by Anne Staylor on 1/14/19 10:00 AM

In an interview with SmartTRAK, B. Todd Sitzman, MD, MPH, President of the North American Neuromodulation Society (NANS), provides a preview of the educational opportunities, key research and emerging technologies that will be at the NANS 22nd Annual meeting to be held January 17-20, 2019 in Las Vegas, NV. Dr. Sitzman expects NANS 2019 to be the biggest meeting yet for the premier neuromodulation society, with up to 3000 attendees and 300+ abstracts presented, organized around the theme of “The Science Behind Successful Outcomes.”

To find out more about the meeting, click on the video below to listen to SmartTRAK’s interview with Dr. Sitzman, recorded via Skype from his office in Hattiesburg, Mississippi (11:53 minutes). 

Read More

Topics: Neuromodulation, SmartTRAK Interviews

SmartTRAK Attending SNIS 2018 - Society of NeuroInterventional Surgery Meeting

Posted by Anne Staylor on 7/20/18 12:05 PM

SmartTRAK is excited to be attending #SNIS - Society of Neuro Interventional Surgery's 15th annual meeting on July 23-26 at the Hilton San Francisco Union Square, in San Francisco, California.

SmartTRAK will be represented by Anne Staylor, Managing Editor, Business Intelligence and Senior Director, Advanced Technologies and Christopher McCarthy, Vice President Corporate Accounts, Orthopedics and Neuro. Please  contact us if you would like a meeting.

Read More

Topics: Neuromodulation, SmartTRAK Conferences

A Look Back: The One to Beat, Nevro's Growth Strategies and Challenges

Posted by Anne Staylor on 6/18/18 4:37 PM

In May 2017, Nevro CEO Rami Elghandour chatted with Anne Staylor, BioMedGPS Managing Editor/Neuro Analyst to discuss dynamics in the global spinal cord stimulation (SCS) market, including trends, drivers, challenges, competition, and opportunity that would influence the Company’s growth. 

A fascinating read then, that now has us appraising a year later if Elghandour's expansion predictions came to pass. Is Nevro still the one to beat as the top leader in the neuromodulation field?

Register to download PDF or read the interview in full below!

Read More

Topics: Neuromodulation, Neurotherapies, Neuromodulation-Spinal Cord Stimulation

What’s Next for Nuvectra? An Interview with CEO Scott Drees

Posted by Anne Staylor on 3/13/18 11:01 AM

Scott Drees, CEO of Nuvectra Corporation, discusses the Company’s challenges and opportunities in 2017, strategies for driving growth and market penetration in neuromodulation, and the Company’s key priorities for 2018 in an interview with SmartTRAK at the North American Neuromodulation Society Annual Meeting held Jan. 11-14, 2018 in Las Vegas, NV.

A transcript of SmartTRAK’s interview with Scott Drees is below, or click the following video to view the interview recorded live at NANS 2018. (17:41 minutes.)

Read More

Topics: Neuromodulation, SmartTRAK Interviews

SmartTRAK Attending ISC 2018 in Los Angeles CA

Posted by Anne Staylor on 1/22/18 9:00 AM

SmartTRAK is excited to be attending #ISC 2018 - International Stroke Conference, January 24-26 at the Los Angeles Convention Center.

The International Stroke Conference is the world’s premier meeting dedicated to the science and treatment of cerebrovascular disease.

Read More

Topics: Neuromodulation, SmartTRAK Conferences

Vagal Nerve Stimulation With Rehab Improves Long-Term Stroke Recovery

Posted by Anne Staylor on 9/26/17 11:47 AM

SmartTRAK reports on two studies presented at INS 2017 evaluating the effect of VNS paired with rehab in stroke patients with upper limb paralysis.

One of the hottest emerging applications for neuromodulation is for improving function and movement in patients paralyzed by a stroke. Stroke affects almost 800,000 people every year in the US alone and is a leading cause of long-term disability, with an annual cost to the healthcare system of ~$33 billion.

At the International Neuromodulation Society (INS) 13th Annual Congress May 26-June 3 in Edinburgh, SmartTRAK interviewed Jesse Dawson, MD, Clinical Lead, Scottish Stroke Research Network, and Teresa Kimberley, PT, PhD Associate Professor, Division of Physical Therapy at the University of Minnesota, regarding a randomized, double-blinded trial evaluating the effect of vagal nerve stimulation (VNS) during stroke rehabilitation on upper limb function after an ischemic stroke using Microtransponder’s Vivistim System...

Read More

Topics: Neuromodulation

SmartTRAK's Neuro Analyst, Anne Staylor, to Attend INS 2017

Posted by Rebecca Gonzalez on 5/25/17 3:18 PM

 SmartTRAK will be at the International Neuromodulation Society 13th World Congress “Neuromodulation: Technology Changing Lives” in Edinburgh, Scotland May 27- June 1. Meet with Anne Staylor, Senior SmartTRAK Analyst and Managing Editor!

Meet with Anne Staylor at INS 2017

Read More

Topics: Neuromodulation, Neurotherapies

Nuvectra: Positioned For Growth In Neuromodulation

Posted by Anne Staylor on 5/4/17 2:00 PM

It’s been less than a year since Nuvectra Medical spun-off from Greatbatch Inc. (now Integer), and in that time Nuvectra has built a sales organization and laid the organizational foundation to become a, multi-indication neurostimulation company.

Read More

Topics: Neuromodulation, Neurotherapies

Finding the Sweet Spot: Medtronic’s Growth Strategies for Spinal Cord Stimulation

Posted by Anne Staylor on 2/25/17 12:00 PM

In an interview with BioMedGPS, Medtronic’s Marshall Stanton, MD discussed the Company’s strategies for gaining back market share in spinal cord stimulation and ongoing efforts to find the sweet spot in treating chronic intractable pain.

Read More

Topics: Neuromodulation

Subscribe to News and Analysis Blog Weekly Emails

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. 

Recent Posts